| Abstract | BACKGROUND: Thrombophlebitis migrans is a major cause of morbidity in approximately 11% of patients with cancer. Thrombosis may predate the appearance of malignancy, and patients with thrombosis often respond poorly to warfarin. METHODS: Four patients with extensive thrombosis and cancer are described in this article. Enoxaparin, a low-molecular-weight heparin, was administered subcutaneously to these patients for 5, 6, 26, and 27 months, respectively. The literature on the management of Trousseau's syndrome was reviewed and analyzed. RESULTS: All four patients remained free of venous thromboembolism while being treated with low-molecular-weight heparin, acutely and during follow-up. Previously published studies suggest that therapy with low-molecular-weight heparin results in lower mortality than standard heparin therapy. CONCLUSIONS: Further study to evaluate the safety and efficacy of low-molecular-weight heparin for both prophylaxis and treatment of thromboembolism in association with malignancy may lead to decreased morbidity and better quality of life for patients with this disorder. |
| Authors | D Walsh-McMonagle, D Green
(Affiliation: Department of Physical Medicine and Rehabilitation, Rehabilitation Institute of Chicago and Northwestern University Medical School, Illinois 60611, USA.)
|
| Journal | Cancer
(Cancer)
Vol. 80
Issue 4
Pg. 649-55
(Aug 15 1997)
ISSN: 0008-543X UNITED STATES |
| PMID | 9264346
(Publication Type: Case Reports, Journal Article)
|
| Chemical References |
- Anticoagulants
- Enoxaparin
|
| Topics |
- Adult
- Anticoagulants
(therapeutic use)
- Enoxaparin
(therapeutic use)
- Female
- Humans
- Male
- Middle Aged
- Neoplasms
(complications)
- Paraneoplastic Syndromes
(drug therapy)
- Thromboembolism
(drug therapy, etiology)
- Thrombosis
(drug therapy, etiology)
|
